Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Uterine Cervical Neoplasms 3Ovarian Neoplasms 3Endometrial Neoplasms 3Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Cystadenocarcinoma, Serous 1Colorectal Neoplasms 1Carcinosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Adenocarcinoma, Mucinous 1

Interventions

Paclitaxel 95Carboplatin 77pembrolizumab 74Cisplatin 29Bevacizumab 27Surveys and Questionnaires 23Radiotherapy 22Letrozole 22Doxorubicin 21Megestrol Acetate 20olaparib 19lenvatinib 19Taxes 17Specimen Handling 17Docetaxel 17Nivolumab 16Magnetic Resonance Spectroscopy 16dostarlimab 15Metformin 15Blood Specimen Collection 14Observation 13Gemcitabine 13Biopsy 13durvalumab 12Medroxyprogesterone Acetate 12Trastuzumab 11Indocyanine Green 11Fulvestrant 11temsirolimus 10abemaciclib 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Axitinib × Gynecologic × Clear all
NCT04458259 2026-06-04

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Pfizer

Phase 1 Terminated
88 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT02912572 2025-07-10

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
106 enrolled 16 charts
Gynecologic

Endometrial Neoplasms

NCT04197219 2020-11-05

Pembrolizumab With Axitinib in Recurrent Endometrial Cancer

Case Comprehensive Cancer Center

Phase 2 Withdrawn
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡